Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer

Cisplatin-based chemotherapy followed by radical cystectomy with bilateral pelvic lymph-node dissection is the current standard for cT2–4a N0 M0 urothelial bladder cancer. Immune checkpoint inhibitors have recently been tested in the neoadjuvant setting with promising pathological and survival resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Raggi, Daniele, Moschini, Marco, Necchi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Open Horizon
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317828/
https://www.ncbi.nlm.nih.gov/pubmed/34337545
http://dx.doi.org/10.1016/j.euros.2021.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317828/
https://www.ncbi.nlm.nih.gov/pubmed/34337545
http://dx.doi.org/10.1016/j.euros.2021.06.001

Ejemplares similares